Aripiprazole (Abilify Maintena) vs Brexpiprazole (Rexulti)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline
Aripiprazole (Abilify Maintena)
Marketed by Otsuka Holdings and partners
NCT00706654 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial with 662 randomized maintenance-phase participants, including 265 assigned to depot 300/400 mg and 266 to oral aripiprazole. The primary clinical relapse endpoint was met: depot treatment was non-inferior to oral aripiprazole, with a difference of -0.64 percentage points and a 95% confidence interval of -5.26 to 3.99, below the prespecified 11.5% margin.
Reported efficacy
Mean change from baseline to endpoint(10th week)in PANSS Total Score. (1st,2nd,4th,6th,8th,10th,12th week): LS mean change from baseline to Week 10 in PANSS Total Score: -33.6 (aripiprazole once-monthly, AOM) vs -34.8 (oral aripiprazole); difference -1.2 (95% CI: -4.1, 1.7), within the pre-defined non-inferiority margin (met)
Result source: NCT03172871
Brexpiprazole (Rexulti)
Marketed by Otsuka Holdings and partners
NCT01393613 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 674 patients with acute schizophrenia, using a validated symptom-severity scale (PANSS) as the primary measure. The pooled comparison of the two higher doses against placebo reached statistical significance (p=0.0093), and the 4 mg dose was significant on its own (p=0.0022), but the 1 mg and 2 mg doses individually did not separate from placebo, so the result was only partially met.
Next expected readout: August 2027 · NCT07742280 (registry estimate)
Reported efficacy
Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score: Change from baseline to Week 6 in PANSS total score: brexpiprazole -22.8 (SE 1.5) vs placebo -17.4 (SE 1.6); least-squares mean difference -5.33, 95% CI -9.55 to -1.10, p=0.014 (met)
Result source: NCT03198078
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aripiprazole (Abilify Maintena) | Brexpiprazole (Rexulti) |
|---|---|---|
| PANSS total, change | -21.5 vs -10.3−11.2 vs placeboNCT016635326 other results
| -16.6 vs -13.5−3.1 vs placeboNCT0139361371 other results
|
| CGI-S, change | -1.2 vs -0.5−0.7 vs placeboNCT016635326 other results
| -1.0 vs -0.8−0.2 vs placeboNCT0139361371 other results
|
| PANSS response | 37% vs 14.3%+22.7 vs placeboNCT01663532 | 38.5% vs 31.7%+6.8 vs placeboNCT013936138 other results
|
| PSP, change | 12.3 vs 5.2+7.1 vs placeboNCT01663532 | 10.5 vs 8.5+2 vs placeboNCT0139361317 other results
|
| Relapse (% of patients) | 10% vs 39.6%−29.6 vs placeboNCT00705783 | 13.5% vs 38.5%−24.9 vs placeboNCT01668797 |
PANSS total, change
- Aripiprazole (Abilify Maintena)
- -21.5 vs -10.3−11.2 vs placeboNCT01663532
6 other results
- -19 vs -9.8 NCT01663532
- -23.7 vs -9.7 NCT01663532
- -15.2 vs -8.3 NCT01663532
- -26.8 vs -11.7 NCT01663532
- -8.9 vs -5 NCT01663532
- -33.6 vs -34.8 NCT03172871
- Brexpiprazole (Rexulti)
- -16.6 vs -13.5−3.1 vs placeboNCT01393613
71 other results
- -20.7 vs -12.0 NCT01396421
- -14.9 vs -7.6 NCT01451164
- -14.1 vs -11.9 NCT01393613
- -14.0 vs -6.6 NCT01451164
- -13.1 vs -11.1 NCT01393613
- -12.3 vs -5.7 NCT01451164
- -10.7 vs -8.9 NCT01393613
- -11 vs -6 NCT01451164
- -8.7 vs -6.6 NCT01393613
- -7.9 vs -4.5 NCT01451164
- -4.3 vs -3.5 NCT01393613
- -4.6 vs -3.1 NCT01451164
- -20 vs -13.5 NCT01393613
- -19.6 vs -12.0 NCT01396421
- -11.5 vs -7.6 NCT01451164
- -17.3 vs -11.9 NCT01393613
- -11.1 vs -6.6 NCT01451164
- -15.6 vs -11.1 NCT01393613
- -11.2 vs -5.7 NCT01451164
- -12.6 vs -8.9 NCT01393613
- -9.4 vs -6 NCT01451164
- -8.4 vs -6.6 NCT01393613
- -6.8 vs -4.5 NCT01451164
- -5.6 vs -3.5 NCT01393613
- -3.4 vs -3.1 NCT01451164
- -16.9 vs -13.5 NCT01393613
- -8.3 vs -7.6 NCT01451164
- -14.5 vs -11.9 NCT01393613
- -8.1 vs -6.6 NCT01451164
- -14.0 vs -11.1 NCT01393613
- -8.4 vs -5.7 NCT01451164
- -11.6 vs -8.9 NCT01393613
- -6.9 vs -6 NCT01451164
- -7.6 vs -6.6 NCT01393613
- -5.1 vs -4.5 NCT01451164
- -3.3 vs -3.5 NCT01393613
- -2.7 vs -3.1 NCT01451164
- -14.9 vs -12.0 NCT01396421
- -22.8 vs -17.4 NCT03198078
- -20 vs -15.9 NCT01810380
- -22.9 vs -19.4 NCT02054702
- -17.9 vs -10.8 NCT01396421
- -14.1 vs -8.9 NCT01396421
- -11.1 vs -7.6 NCT01396421
- -8.9 vs -5.1 NCT01396421
- -4.9 vs -2.9 NCT01396421
- -18.6 vs -10.8 NCT01396421
- -16.5 vs -8.9 NCT01396421
- -12.8 vs -7.6 NCT01396421
- -9.5 vs -5.1 NCT01396421
- -4.4 vs -2.9 NCT01396421
- -11.9 vs -10.8 NCT01396421
- -8.9 vs -8.9 NCT01396421
- -5.7 vs -7.6 NCT01396421
- -3.3 vs -5.1 NCT01396421
- -2.5 vs -2.9 NCT01396421
- 0.8 vs 4.1 NCT01668797
- 0.5 vs 3.6 NCT01668797
- 0.8 vs 6.2 NCT01668797
- 1.6 vs 6.6 NCT01668797
- -1.9 vs 2.9 NCT01668797
- 1.6 vs 9.2 NCT01668797
- -2.7 vs 3.3 NCT01668797
- 2.5 vs 10.5 NCT01668797
- 0.6 vs 6.9 NCT01668797
- 3.3 vs 11.2 NCT01668797
- -9.8 vs -14.4 NCT00905307
- -18.7 vs -14.4 NCT00905307
- -16.2 vs -14.4 NCT00905307
- -18.3 vs -14.4 NCT00905307
- -3.7 vs -0.3 NCT03526354
CGI-S, change
- Aripiprazole (Abilify Maintena)
- -1.2 vs -0.5−0.7 vs placeboNCT01663532
6 other results
- -1 vs -0.4 NCT01663532
- -1.3 vs -0.6 NCT01663532
- -0.8 vs -0.4 NCT01663532
- -1.4 vs -0.6 NCT01663532
- -0.4 vs -0.2 NCT01663532
- -0.8 vs -0.5 NCT01795547
- Brexpiprazole (Rexulti)
- -1.0 vs -0.8−0.2 vs placeboNCT01393613
71 other results
- -1.1 vs -0.8 NCT01396421
- -0.8 vs -0.6 NCT01451164
- -0.8 vs -0.7 NCT01393613
- -1.0 vs -0.7 NCT01396421
- -0.8 vs -0.5 NCT01451164
- -0.7 vs -0.6 NCT01393613
- -0.7 vs -0.5 NCT01396421
- -0.6 vs -0.4 NCT01451164
- -0.6 vs -0.4 NCT01393613
- -0.6 vs -0.5 NCT01396421
- -0.5 vs -0.4 NCT01451164
- -0.4 vs -0.4 NCT01393613
- -0.4 vs -0.3 NCT01396421
- -0.4 vs -0.3 NCT01451164
- -0.2 vs -0.1 NCT01393613
- -0.2 vs -0.1 NCT01396421
- -0.2 vs -0.1 NCT01451164
- -1.2 vs -0.8 NCT01393613
- -1.2 vs -0.8 NCT01396421
- -0.6 vs -0.6 NCT01451164
- -1.0 vs -0.7 NCT01393613
- -1.1 vs -0.7 NCT01396421
- -0.6 vs -0.5 NCT01451164
- -0.8 vs -0.6 NCT01393613
- -1.0 vs -0.5 NCT01396421
- -0.5 vs -0.4 NCT01451164
- -0.7 vs -0.4 NCT01393613
- -0.7 vs -0.5 NCT01396421
- -0.5 vs -0.4 NCT01451164
- -0.4 vs -0.4 NCT01393613
- -0.5 vs -0.3 NCT01396421
- -0.3 vs -0.3 NCT01451164
- -0.2 vs -0.1 NCT01393613
- -0.2 vs -0.1 NCT01396421
- -0.1 vs -0.1 NCT01451164
- -0.9 vs -0.8 NCT01393613
- -0.5 vs -0.6 NCT01451164
- -0.8 vs -0.7 NCT01393613
- -0.5 vs -0.5 NCT01451164
- -0.7 vs -0.6 NCT01393613
- -0.5 vs -0.4 NCT01451164
- -0.6 vs -0.4 NCT01393613
- -0.4 vs -0.4 NCT01451164
- -0.3 vs -0.4 NCT01393613
- -0.3 vs -0.3 NCT01451164
- -0.1 vs -0.1 NCT01393613
- -0.1 vs -0.1 NCT01451164
- -0.8 vs -0.8 NCT01396421
- -0.7 vs -0.7 NCT01396421
- -0.6 vs -0.5 NCT01396421
- -0.3 vs -0.5 NCT01396421
- -0.2 vs -0.3 NCT01396421
- -0.1 vs -0.1 NCT01396421
- -0.9 vs -0.8 NCT03198078
- -0.0 vs 0.3 NCT01668797
- -0.1 vs 0.2 NCT01668797
- -1.2 vs -0.9 NCT01810380
- -0.0 vs 0.4 NCT01668797
- -0.0 vs 0.3 NCT01668797
- -0.2 vs 0.2 NCT01668797
- -0.0 vs 0.5 NCT01668797
- -0.3 vs 0.3 NCT01668797
- 0 vs 0.6 NCT01668797
- -0.2 vs 0.3 NCT01668797
- 0.0 vs 0.6 NCT01668797
- -1.6 vs -1.3 NCT02054702
- -0.4 vs -0.8 NCT00905307
- -1.0 vs -0.8 NCT00905307
- -0.9 vs -0.8 NCT00905307
- -1.1 vs -0.8 NCT00905307
- -0.3 vs -0.1 NCT03526354
PANSS response
- Aripiprazole (Abilify Maintena)
- 37% vs 14.3%+22.7 vs placeboNCT01663532
- Brexpiprazole (Rexulti)
- 38.5% vs 31.7%+6.8 vs placeboNCT01393613
8 other results
- 49.7% vs 31.7% NCT01393613
- 43.6% vs 31.7% NCT01393613
- 43.6% vs 28.2% NCT03198078
- 48.7% vs 32.1% NCT01810380
- 40.5% vs 49.5% NCT00905307
- 57.3% vs 49.5% NCT00905307
- 46.7% vs 49.5% NCT00905307
- 51.6% vs 49.5% NCT00905307
PSP, change
- Aripiprazole (Abilify Maintena)
- 12.3 vs 5.2+7.1 vs placeboNCT01663532
- Brexpiprazole (Rexulti)
- 10.5 vs 8.5+2 vs placeboNCT01393613
17 other results
- 13.2 vs 10.3 NCT01396421
- 6.8 vs 5.8 NCT01393613
- 13.1 vs 8.5 NCT01393613
- 12.7 vs 10.3 NCT01396421
- 7.1 vs 5.8 NCT01393613
- 11.7 vs 8.5 NCT01393613
- 7.0 vs 5.8 NCT01393613
- 11.8 vs 10.3 NCT01396421
- 18.6 vs 12.6 NCT01668797
- 15.1 vs 10.3 NCT01668797
- 18.9 vs 17.8 NCT01668797
- 15.2 vs 11.4 NCT01668797
- 13 vs 9.4 NCT01810380
- 4.5 vs 7.6 NCT00905307
- 11.4 vs 7.6 NCT00905307
- 10.7 vs 7.6 NCT00905307
- 12.2 vs 7.6 NCT00905307
Relapse (% of patients)
- Aripiprazole (Abilify Maintena)
- 10% vs 39.6%−29.6 vs placeboNCT00705783
- Brexpiprazole (Rexulti)
- 13.5% vs 38.5%−24.9 vs placeboNCT01668797
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
11 other shared endpoints and safety
Coverage. Aripiprazole (Abilify Maintena): 15 of 15 rows · Brexpiprazole (Rexulti): 15 of 15 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aripiprazole (Abilify Maintena) Rows use multiple source trials | Brexpiprazole (Rexulti) Rows use multiple source trials |
|---|---|---|
| CGI-I absolute value · score | 2.7 vs 3.7 placebo score @ 10wk400/300 mga,b,c NCT01663532 · Phase 3 | 3.77 vs 4.4 placebo score @ 52wka,b,c NCT01668797 · Phase 3 |
| CGI-I absolute value · score No placebo or comparator arm | 3.25 score @ 52wk400/300 mg IM Depota,b,d NCT00731549 · Phase 3 · registry result, not featured evidence | 1.9 scoree,a,b,d NCT03238326 · Phase 3 show 3 more doses2.1 score NCT03238326 · Phase 3 2.1 score NCT03238326 · Phase 3 2.2 score NCT03238326 · Phase 3 |
| CGI-S absolute change · score No placebo or comparator arm | -0.24 score @ 52wk400/300 mg IM Depota,b NCT00731549 · Phase 3 · registry result, not featured evidence | -0.48 score @ 52wke,a,b NCT01397786 · Phase 3 · registry result, not featured evidence show 2 more doses-0.55 score @ 52wk NCT01397786 · Phase 3 · registry result, not featured evidence -0.97 score @ 52wk NCT01397786 · Phase 3 · registry result, not featured evidence |
| PANSS Negative absolute change · score No placebo or comparator arm | -0.96 score @ 4wk400mge,f,a,b,g NCT01552772 · Phase 1 · registry result, not featured evidence show 1 more dose-0.92 score @ 4wk400mg NCT01552772 · Phase 1 · registry result, not featured evidence | -2 score @ 52wke,f,a,b,g NCT01397786 · Phase 3 · registry result, not featured evidence show 2 more doses-2.7 score @ 52wk NCT01397786 · Phase 3 · registry result, not featured evidence -3.7 score @ 52wk NCT01397786 · Phase 3 · registry result, not featured evidence |
| PANSS Negative Subscale absolute change · score | -3.5 vs -1.3 placebo score @ 6wk400/300 mga,b NCT01663532 · Phase 3 | -4.02 vs -2.24 placebo score @ 6wk2 mge,a,b NCT01396421 · Phase 3 show 2 more doses-3.65 vs -2.24 placebo score @ 6wk4 mg NCT01396421 · Phase 3 -3.31 vs -2.24 placebo score @ 6wk0.25 mg NCT01396421 · Phase 3 |
| PANSS Negative Subscale absolute change · score No placebo or comparator arm | -0.33 score @ 20wk400 mgf,a,b,d NCT01909466 · Phase 1 · registry result, not featured evidence | -4.4 scoree,f,a,b,d NCT03238326 · Phase 3 show 3 more doses-4.82 score NCT03238326 · Phase 3 -4.89 score NCT03238326 · Phase 3 -4.55 score NCT03238326 · Phase 3 |
| PANSS Positive absolute change · score No placebo or comparator arm | -1.28 score @ 4wk400mge,f,a,b,g NCT01552772 · Phase 1 · registry result, not featured evidence show 1 more dose-1.25 score @ 4wk400mg NCT01552772 · Phase 1 · registry result, not featured evidence | -2.3 score @ 52wke,f,a,b,g NCT01397786 · Phase 3 · registry result, not featured evidence show 2 more doses-3.2 score @ 52wk NCT01397786 · Phase 3 · registry result, not featured evidence -5.8 score @ 52wk NCT01397786 · Phase 3 · registry result, not featured evidence |
| PANSS Positive Subscale absolute change · score | -8.2 vs -4.4 placebo score @ 6wk400/300 mga,b NCT01663532 · Phase 3 | -6.57 vs -4.35 placebo score @ 6wk2 mge,a,b NCT01396421 · Phase 3 show 2 more doses-6.78 vs -4.35 placebo score @ 6wk4 mg NCT01396421 · Phase 3 -5.46 vs -4.35 placebo score @ 6wk0.25 mg NCT01396421 · Phase 3 |
| PANSS Positive Subscale absolute change · score No placebo or comparator arm | -0.52 score @ 20wk400 mgf,a,b,d NCT01909466 · Phase 1 · registry result, not featured evidence | -5.15 scoree,f,a,b,d NCT03238326 · Phase 3 show 3 more doses-4.59 score NCT03238326 · Phase 3 -5.2 score NCT03238326 · Phase 3 -5.29 score NCT03238326 · Phase 3 |
| PANSS Total absolute change · score No placebo or comparator arm | -3.55 score @ 52wk400/300 mg IM Depota,b,d NCT00731549 · Phase 3 · registry result, not featured evidence | -19 scoree,a,b,d NCT03238326 · Phase 3 show 3 more doses-18.44 score NCT03238326 · Phase 3 -20.14 score NCT03238326 · Phase 3 -19.76 score NCT03238326 · Phase 3 |
| QLS Total absolute change · score | 70.05 vs 62.21 Clinician's Choice score @ 104wka,b,h NCT02360319 · Phase 4 · registry result, not featured evidence | 4.049 vs -5.146 Treatment as Usual score @ 12wka,b,h NCT03526354 · Phase 4 · registry result, not featured evidence |
| Dropout rate | —300 or 400 mgi NCT00706654 · Phase 3 show 13 more results—25 or 50 mg NCT00706654 · Phase 3 —Aripiprazole Depot NCT00705783 · Phase 3 · monotherapy —Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · monotherapy 44%400/300 mg NCT01663532 · Phase 3 26.1% NCT02360319 · Phase 4 · registry result, not featured evidence 12.5% NCT01959035 · Phase 3 · registry result, not featured evidence 32.4% NCT01795547 · Phase 3 · registry result, not featured evidence 39.2%400/300 mg NCT01683058 · Phase 3 · registry result, not featured evidence 20.6%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence —400 mg NCT01909466 · Phase 1 · registry result, not featured evidence 11.1%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 26.3%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 6.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence | 30.6%2 mgi NCT01393613 · Phase 3 show 45 more results29.3%4 mg NCT01393613 · Phase 3 32.5%1 mg NCT01393613 · Phase 3 —2 mg NCT01396421 · Phase 3 31.9%2 mg NCT01396421 · Phase 3 32.8%4 mg NCT01396421 · Phase 3 —4 mg NCT01396421 · Phase 3 —0.25 mg NCT01396421 · Phase 3 37.8%0.25 mg NCT01396421 · Phase 3 0%De Novo (Conversion Period) NCT03238326 · Phase 3 —De Novo (OLT Period) NCT03238326 · Phase 3 —Prior & Current Brexpiprazole (OLT NCT03238326 · Phase 3 —Prior Aripiprazole & Current Brexp NCT03238326 · Phase 3 —Prior Placebo & Current Brexpipraz NCT03238326 · Phase 3 —Prior and Current Brexpiprazole NCT03238326 · Phase 3 2.7% NCT03198078 · Phase 3 — NCT01668797 · Phase 3 28.6% NCT03526354 · Phase 4 · registry result, not featured evidence 15.8%2 mg NCT02194933 · Phase 3 · registry result, not featured evidence 47.4%4 mg NCT02194933 · Phase 3 · registry result, not featured evidence 12.3%De Novo NCT01397786 · Phase 3 · registry result, not featured evidence —De Novo (Phase A) NCT01397786 · Phase 3 · registry result, not featured evidence —De Novo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 0%Prior Brexpiprazole NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Brexpiprazole (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 51.9% NCT01810783 · Phase 3 · registry result, not featured evidence 25.2% NCT01810380 · Phase 3 · registry result, not featured evidence 49% NCT02013622 · Phase 3 · registry result, not featured evidence 37.5% NCT02054702 · Phase 3 · registry result, not featured evidence 29.6%2 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 39.8%4 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 37.4%1 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 52.4%0.25 mg NCT00905307 · Phase 2 · registry result, not featured evidence —High-dose NCT00905307 · Phase 2 · registry result, not featured evidence 41.6%Low-dose NCT00905307 · Phase 2 · registry result, not featured evidence 41.1%Mid-dose NCT00905307 · Phase 2 · registry result, not featured evidence —Fasted Stated NCT06036108 · Phase 1 · registry result, not featured evidence —Fed Stated NCT06036108 · Phase 1 · registry result, not featured evidence 0%4 mg NCT01854944 · Phase 1 · registry result, not featured evidence 25%4 mg NCT01854944 · Phase 1 · registry result, not featured evidence 0%1 mg NCT01854944 · Phase 1 · registry result, not featured evidence 14.9%4 mg NCT01423916 · Phase 1 · registry result, not featured evidence 27.4%12 mg NCT01423916 · Phase 1 · registry result, not featured evidence —3mg NCT01289080 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —300 or 400 mgi NCT00706654 · Phase 3 show 13 more results—25 or 50 mg NCT00706654 · Phase 3 —Aripiprazole Depot NCT00705783 · Phase 3 · monotherapy —Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · monotherapy 4.2%400/300 mg NCT01663532 · Phase 3 — NCT02360319 · Phase 4 · registry result, not featured evidence 5.7% NCT01959035 · Phase 3 · registry result, not featured evidence 10.8% NCT01795547 · Phase 3 · registry result, not featured evidence 8.1%400/300 mg NCT01683058 · Phase 3 · registry result, not featured evidence 2.9%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence —400 mg NCT01909466 · Phase 1 · registry result, not featured evidence —400 mg NCT01646827 · Phase 1 · registry result, not featured evidence —400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 1.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence | 5.9%2 mgi NCT01393613 · Phase 3 show 45 more results7.1%4 mg NCT01393613 · Phase 3 9.2%1 mg NCT01393613 · Phase 3 —2 mg NCT01396421 · Phase 3 8.2%2 mg NCT01396421 · Phase 3 9.4%4 mg NCT01396421 · Phase 3 —4 mg NCT01396421 · Phase 3 —0.25 mg NCT01396421 · Phase 3 13.3%0.25 mg NCT01396421 · Phase 3 —De Novo (Conversion Period) NCT03238326 · Phase 3 —De Novo (OLT Period) NCT03238326 · Phase 3 —Prior & Current Brexpiprazole (OLT NCT03238326 · Phase 3 —Prior Aripiprazole & Current Brexp NCT03238326 · Phase 3 —Prior Placebo & Current Brexpipraz NCT03238326 · Phase 3 —Prior and Current Brexpiprazole NCT03238326 · Phase 3 0% NCT03198078 · Phase 3 — NCT01668797 · Phase 3 — NCT03526354 · Phase 4 · registry result, not featured evidence —2 mg NCT02194933 · Phase 3 · registry result, not featured evidence —4 mg NCT02194933 · Phase 3 · registry result, not featured evidence 3.5%De Novo NCT01397786 · Phase 3 · registry result, not featured evidence —De Novo (Phase A) NCT01397786 · Phase 3 · registry result, not featured evidence —De Novo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 0%Prior Brexpiprazole NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Brexpiprazole (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 15.2% NCT01810783 · Phase 3 · registry result, not featured evidence 9.3% NCT01810380 · Phase 3 · registry result, not featured evidence 6.1% NCT02013622 · Phase 3 · registry result, not featured evidence 4.7% NCT02054702 · Phase 3 · registry result, not featured evidence 10.4%2 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 15.9%4 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 16.5%1 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 7.1%0.25 mg NCT00905307 · Phase 2 · registry result, not featured evidence —High-dose NCT00905307 · Phase 2 · registry result, not featured evidence 4.5%Low-dose NCT00905307 · Phase 2 · registry result, not featured evidence 5.6%Mid-dose NCT00905307 · Phase 2 · registry result, not featured evidence —Fasted Stated NCT06036108 · Phase 1 · registry result, not featured evidence —Fed Stated NCT06036108 · Phase 1 · registry result, not featured evidence —4 mg NCT01854944 · Phase 1 · registry result, not featured evidence —4 mg NCT01854944 · Phase 1 · registry result, not featured evidence —1 mg NCT01854944 · Phase 1 · registry result, not featured evidence 6.8%4 mg NCT01423916 · Phase 1 · registry result, not featured evidence 12.3%12 mg NCT01423916 · Phase 1 · registry result, not featured evidence —3mg NCT01289080 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 5.7%300 or 400 mgi NCT00706654 · Phase 3 show 13 more results8.4%25 or 50 mg NCT00706654 · Phase 3 —Aripiprazole Depot NCT00705783 · Phase 3 · monotherapy 4.1%Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · monotherapy 4.8%400/300 mg NCT01663532 · Phase 3 29.1% NCT02360319 · Phase 4 · registry result, not featured evidence 3.4% NCT01959035 · Phase 3 · registry result, not featured evidence 8.3% NCT01795547 · Phase 3 · registry result, not featured evidence 6.8%400/300 mg NCT01683058 · Phase 3 · registry result, not featured evidence 8.8%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence 2.9%400 mg NCT01909466 · Phase 1 · registry result, not featured evidence 0%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 0%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 1.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence | 2.2%2 mgi NCT01393613 · Phase 3 show 45 more results2.2%4 mg NCT01393613 · Phase 3 2.5%1 mg NCT01393613 · Phase 3 2.2%2 mg NCT01396421 · Phase 3 —2 mg NCT01396421 · Phase 3 —4 mg NCT01396421 · Phase 3 1.1%4 mg NCT01396421 · Phase 3 4.4%0.25 mg NCT01396421 · Phase 3 —0.25 mg NCT01396421 · Phase 3 0%De Novo (Conversion Period) NCT03238326 · Phase 3 5%De Novo (OLT Period) NCT03238326 · Phase 3 —Prior & Current Brexpiprazole (OLT NCT03238326 · Phase 3 1.1%Prior Aripiprazole & Current Brexp NCT03238326 · Phase 3 3.4%Prior Placebo & Current Brexpipraz NCT03238326 · Phase 3 4.1%Prior and Current Brexpiprazole NCT03238326 · Phase 3 0.9% NCT03198078 · Phase 3 3.1% NCT01668797 · Phase 3 0% NCT03526354 · Phase 4 · registry result, not featured evidence 0%2 mg NCT02194933 · Phase 3 · registry result, not featured evidence 0%4 mg NCT02194933 · Phase 3 · registry result, not featured evidence —De Novo NCT01397786 · Phase 3 · registry result, not featured evidence 1.8%De Novo (Phase A) NCT01397786 · Phase 3 · registry result, not featured evidence 11.2%De Novo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Brexpiprazole NCT01397786 · Phase 3 · registry result, not featured evidence 14.9%Prior Brexpiprazole (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo NCT01397786 · Phase 3 · registry result, not featured evidence 8.9%Prior Placebo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 14.8% NCT01810783 · Phase 3 · registry result, not featured evidence 4.7% NCT01810380 · Phase 3 · registry result, not featured evidence 0% NCT02013622 · Phase 3 · registry result, not featured evidence 4.7% NCT02054702 · Phase 3 · registry result, not featured evidence 4.4%2 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 4.4%4 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 7%1 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 0%0.25 mg NCT00905307 · Phase 2 · registry result, not featured evidence 4.3%High-dose NCT00905307 · Phase 2 · registry result, not featured evidence 3.4%Low-dose NCT00905307 · Phase 2 · registry result, not featured evidence 5.6%Mid-dose NCT00905307 · Phase 2 · registry result, not featured evidence 0%Fasted Stated NCT06036108 · Phase 1 · registry result, not featured evidence 1.8%Fed Stated NCT06036108 · Phase 1 · registry result, not featured evidence 0%4 mg NCT01854944 · Phase 1 · registry result, not featured evidence 0%4 mg NCT01854944 · Phase 1 · registry result, not featured evidence 0%1 mg NCT01854944 · Phase 1 · registry result, not featured evidence 1.4%4 mg NCT01423916 · Phase 1 · registry result, not featured evidence 0%12 mg NCT01423916 · Phase 1 · registry result, not featured evidence 0%3mg NCT01289080 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | show 12 more resultsinsomnia 10% (placebo 9%) weight increased 9.7% (placebo 9.7%) anxiety 5.9% (placebo 7.5%) NCT00705783 · Phase 3 · monotherapy 400/300 mg weight increased 16.8% (placebo 7%) headache 14.4% (placebo 16.3%) akathisia 11.4% (placebo 3.5%) NCT01663532 · Phase 3 weight gain 14.4% anxiety 12.2% depression 10.4% NCT02360319 · Phase 4 · registry result, not featured evidence weight increased 6.8% NCT01959035 · Phase 3 · registry result, not featured evidence accidental overdose 20.8% insomnia 11.8% weight increased 9% NCT01795547 · Phase 3 · registry result, not featured evidence 400/300 mg weight increased 29.7% akathisia 12.2% headache 8.1% NCT01683058 · Phase 3 · registry result, not featured evidence 400/300 mg IM Depot headache 7.6% nasopharyngitis 7% anxiety 6.8% NCT00731549 · Phase 3 · registry result, not featured evidence 400 mg injection site pain 27.5% weight increased 12.3% headache 11.6% NCT01909466 · Phase 1 · registry result, not featured evidence 400 mg injection site pain 35.3% headache 23.5% akathisia 17.6% NCT01646827 · Phase 1 · registry result, not featured evidence 400 mg injection site pain 27.8% headache 22.2% akathisia 16.7% NCT01646827 · Phase 1 · registry result, not featured evidence 400mg injection site pain 6.7% toothache 6.7% blood creatine phosphokinase increased 5% NCT01552772 · Phase 1 · registry result, not featured evidence | 2 mgi insomnia 13.4% (placebo 14.7%) headache 10.8% (placebo 14.7%) agitation 8.6% (placebo 7.1%) NCT01393613 · Phase 3 show 38 more results4 mg insomnia 15.2% (placebo 14.7%) headache 10.3% (placebo 14.7%) agitation 7.1% (placebo 7.1%) NCT01393613 · Phase 3 1 mg insomnia 12.5% (placebo 14.7%) agitation 8.3% (placebo 7.1%) headache 7.5% (placebo 14.7%) NCT01393613 · Phase 3 2 mg headache 9.3% (placebo 8.2%) insomnia 8.8% (placebo 9.8%) agitation 6% (placebo 10.3%) NCT01396421 · Phase 3 4 mg headache 12.2% (placebo 8.2%) insomnia 8.3% (placebo 9.8%) agitation 7.2% (placebo 10.3%) NCT01396421 · Phase 3 0.25 mg headache 10% (placebo 8.2%) insomnia 8.9% (placebo 9.8%) schizophrenia 6.7% (placebo 9.8%) NCT01396421 · Phase 3 headache 6.4% (placebo 4.8%) nausea 6.4% (placebo 3.8%) somnolence 4.5% (placebo 4.8%) NCT03198078 · Phase 3 fatigure/tiredness 14.3% nausea 14.3% cold-like symptoms 9.5% NCT03526354 · Phase 4 · registry result, not featured evidence 2 mg headache 15.8% insomnia 10.5% irritability 10.5% NCT02194933 · Phase 3 · registry result, not featured evidence 4 mg agitation 10.5% anxiety 10.5% back pain 10.5% NCT02194933 · Phase 3 · registry result, not featured evidence insomnia 12.5% headache 9.4% agitation 9% NCT01397786 · Phase 3 · registry result, not featured evidence insomnia 8.4% weight increased 7.8% headache 6.9% NCT01397786 · Phase 3 · registry result, not featured evidence insomnia 8.4% weight increased 7.4% akathisia 6.9% NCT01397786 · Phase 3 · registry result, not featured evidence weight increased 10.5% headache 8.6% insomnia 8.1% NCT01810783 · Phase 3 · registry result, not featured evidence insomnia 8.7% (placebo 6.2%) akathisia 6% (placebo 2.5%) headache 5.3% (placebo 6.8%) NCT01810380 · Phase 3 · registry result, not featured evidence insomnia 14.3% somnolence 8.2% nausea 6.1% NCT02013622 · Phase 3 · registry result, not featured evidence akathisia 9.4% weight increased 9.4% dry mouth 7.8% NCT02054702 · Phase 3 · registry result, not featured evidence 2 mg schizophrenia 11.4% (placebo 24.1%) headache 7.9% (placebo 4.3%) constipation 7% (placebo 7.8%) NCT01451164 · Phase 2/3 · registry result, not featured evidence 4 mg schizophrenia 20.4% (placebo 24.1%) nasopharyngitis 8.8% (placebo 9.5%) vomiting 7.1% (placebo 3.4%) NCT01451164 · Phase 2/3 · registry result, not featured evidence 1 mg schizophrenia 17.4% (placebo 24.1%) nasopharyngitis 10.4% (placebo 9.5%) constipation 7% (placebo 7.8%) NCT01451164 · Phase 2/3 · registry result, not featured evidence 0.25 mg headache 14.3% (placebo 10.5%) anxiety 11.9% (placebo 10.5%) agitation 9.5% (placebo 4.2%) NCT00905307 · Phase 2 · registry result, not featured evidence High-dose akathisia 15.1% (placebo 4.2%) anxiety 10.8% (placebo 10.5%) insomnia 9.7% (placebo 16.8%) NCT00905307 · Phase 2 · registry result, not featured evidence Low-dose insomnia 13.5% (placebo 16.8%) headache 9% (placebo 10.5%) anxiety 7.9% (placebo 10.5%) NCT00905307 · Phase 2 · registry result, not featured evidence Mid-dose headache 14.4% (placebo 10.5%) insomnia 10% (placebo 16.8%) weight increased 10% (placebo 3.2%) NCT00905307 · Phase 2 · registry result, not featured evidence nausea 9.6% somnolence 9.6% diarrhoea 5.8% NCT06036108 · Phase 1 · registry result, not featured evidence vomiting 20% nausea 12.7% somnolence 12.7% NCT06036108 · Phase 1 · registry result, not featured evidence 4 mg abdominal pain 25% akathisia 25% blepharospasm 25% NCT01854944 · Phase 1 · registry result, not featured evidence 4 mg akathisia 25% dental carries 25% dyspepsia 25% NCT01854944 · Phase 1 · registry result, not featured evidence 1 mg abdominal discomfort 50% agitation 25% abdominal pain 0% NCT01854944 · Phase 1 · registry result, not featured evidence 4 mg nausea 10% (placebo 5.9%) application site dermatitis 8.6% (placebo 5.9%) dizziness 8.6% (placebo 1.5%) NCT01423916 · Phase 1 · registry result, not featured evidence 12 mg dizziness 11.9% (placebo 1.5%) akathisia 7.5% (placebo 1.5%) extrapyramidal disorder 7.5% (placebo 1.5%) NCT01423916 · Phase 1 · registry result, not featured evidence 3mg somnolence 15.8% headache 10.5% orthostatic hypotension 10.5% NCT01289080 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 52 weeks versus 10 weeks.
- dThe assessment timepoint is not available for both results.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fTrial phases differ: Phase 3 versus Phase 1.
- gAssessment timepoints differ: 52 weeks versus 4 weeks.
- hAssessment timepoints differ: 12 weeks versus 104 weeks.
- iPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aripiprazole (Abilify Maintena)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 20 further endpoints in the CSV export.
Brexpiprazole (Rexulti)
show 35 more results
show 35 more results
show 31 more results
show 31 more results
show 31 more results
show 28 more results
show 31 more results
show 31 more results
show 3 more results
show 2 more results
show 3 more results
show 3 more results
+ 44 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole (Abilify Maintena)'s landscape · Brexpiprazole (Rexulti)'s landscape